Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer

Hung,Ming‑Szu; Chen,I‑Chuan; Lin,Paul‑Yann; Lung,Jr‑Hau; Li,Ya‑Chin; Lin,Yu‑Ching; Yang,Cheng‑Ta; Tsai,Ying‑Huang

doi:10.3892/ol.2016.5287

Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer

Authors:
- Ming‑Szu Hung
- I‑Chuan Chen
- Paul‑Yann Lin
- Jr‑Hau Lung
- Ya‑Chin Li
- Yu‑Ching Lin
- Cheng‑Ta Yang
- Ying‑Huang Tsai
View Affiliations

Affiliations: Division of Thoracic Oncology, Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Puzih, Chiayi 61363, Taiwan, R.O.C., Department of Emergency Medicine, Chang Gung Memorial Hospital, Puzih, Chiayi 61363, Taiwan, R.O.C., Department of Anatomic Pathology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan, R.O.C., Division of Pulmonary and Critical Care Medicine, Chang‑Gung Memorial Hospital, Taoyuan 33305, Taiwan, R.O.C.
Published online on: October 18, 2016 https://doi.org/10.3892/ol.2016.5287
Pages: 4598-4604
Copyright: © Hung et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidermal growth factor receptor (EGFR) activation has been demonstrated to have a critical role in tumor angiogenesis. In the present study, the correlation between EGFR mutations and vascular endothelial growth factor (VEGF) was investigated in lung cancer cell lines and non‑small‑cell lung cancer (NSCLC) tumor tissues. VEGF levels were significantly increased in culture medium of lung cancer cells and NSCLC tissues with EGFR mutations (H1650 vs. A549, P=0.0399; H1975 vs. A549, P<0.0001). Stable lung cancer cell lines expressing mutant (exon 19 deletion, E746‑A750; exon 21 missense mutation, L858R) and wild‑type EGFR genes were established. Significantly increased expression of VEGF and stronger inhibitory effects of gefitinib to VEGF expression were observed in exon 19 deletion stable lung cancer cells (exon 19 deletion vs. wild‑type EGFR, P=0.0005). The results of the present study may provide an insight into the association of mutant EGFR and VEGF expression in lung cancer, and may assist with further development of targeted therapy for NSCLC in the future.

View Figures

View References

1	Arteaga CL: Epidermal growth factor receptor dependence in human tumors: More than just expression? Oncologist. 4:(Supp 7). S31–S39. 2002. View Article : Google Scholar
2	Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
3	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
4	Gazdar AF, Shigematsu H, Herz J and Minna JD: Mutations and addiction to EGFR: The Achilles ‘heal’ of lung cancers? Trends Mol Med. 10:481–486. 2004. View Article : Google Scholar : PubMed/NCBI
5	Hsieh RK, Lim KH, Kuo HT, Tzen CY and Huang MJ: Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest. 128:317–321. 2005. View Article : Google Scholar : PubMed/NCBI
6	Shih JY, Gow CH, Yu CJ, et al: Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer. 118:963–969. 2006. View Article : Google Scholar : PubMed/NCBI
7	Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C and Van Waes C: Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer. 99:538–548. 2002. View Article : Google Scholar : PubMed/NCBI
8	Goldman CK, Kim J, Wong WL, King V, Brock T and Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 4:121–133. 1993. View Article : Google Scholar : PubMed/NCBI
9	Ravindranath N, Wion D, Brachet P and Djakiew D: Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl. 22:432–443. 2001.PubMed/NCBI
10	Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M and Ono M: ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62:2554–2560. 2002.PubMed/NCBI
11	Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR and Tortora G: Inhibition of growth factor production and angiogenesis in human cancer cells by Z (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 7:1459–1465. 2001.PubMed/NCBI
12	Ferrara N: Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev. 25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI
13	Shimanuki Y, Takahashi K, Cui R, Hori S, Takahashi F, Miyamoto H and Fukurchi Y: Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung. 183:29–42. 2005. View Article : Google Scholar : PubMed/NCBI
14	Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
15	Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, Sonenberg N, Hynes RO and Kalluri R: Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science. 295:140–143. 2002. View Article : Google Scholar : PubMed/NCBI
16	Cote ML, Haddad R, Edwards DJ, Atikukke G, Gadgeel S, Soubani AO, Lonardo F, Bepler G, Schwartz AG and Ethier SP: Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol. 6:627–630. 2011. View Article : Google Scholar : PubMed/NCBI
17	Jia SF, Guan H, Duan X and Kleinerman ES: VEGF165 is necessary to the metastatic potential of Fas (−) osteosarcoma cells but will not rescue the Fas (+) cells. J Exp Ther Oncol. 7:89–97. 2008.PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Reinmuth N, Jauch A, Xu EC, Muley T, Granzow M, Hoffmann H, Dienemann H, Herpel E, Schnabel PA, Herth FJ, et al: Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung cancer. 62:193–201. 2008. View Article : Google Scholar : PubMed/NCBI
20	Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI
21	Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P, Sanchez JM, Nishiyama K, Moran T, Cirauqui B, et al: Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer. 50:25–33. 2005. View Article : Google Scholar : PubMed/NCBI
22	Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
24	Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B and Bromberg JF: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 117:3846–3856. 2007. View Article : Google Scholar : PubMed/NCBI
25	Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R and Fidler IJ: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60:2926–2935. 2000.PubMed/NCBI
26	Sun L, Ma JT, Zhang SL, Zou HW and Han CB: Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: A systematic review and meta-analysis. Med Oncol. 32:4732015. View Article : Google Scholar : PubMed/NCBI